A Phase 1 interventional study of AV-380 in Cachexia, sponsored by AVEO Pharmaceuticals, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.
Among the 95 studies in Cachexia with a site in United States, this one is the 48th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2023, is one of 21 in phase 1, and was the 87th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
CatalYm GmbH · Sites in United States, Bulgaria, Czechia and 11 more countries
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Endevica Bio · Sites in United States, Canada
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 26 · Phase 3 20 · Phase 4 2
First in 1997; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 51 across the 72 interventional studies, 36 across the 16 observational. Of the 82 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 95 have an industry lead sponsor. The 10 most frequent:
This study is registered under AVEO Pharmaceuticals, Inc., one of the names counted as LG Chem. Under that name alone:
AVEO Pharmaceuticals, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
LG Chem has 3 studies filed under Cachexia — fewer than ten, so there is no comparison to draw.
4 of the studies in Cachexia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06721260University of Kansas Medical CenterMetabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS) | 2027-01 |
| NCT07146893University of OklahomaFeasibility Study for Repurposing RET Inhibitors | 2027-02-23 |
| NCT05705492OHSU Knight Cancer InstituteOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | 2027-06-30 |
| NCT06937177Endevica BioSafely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 95 studies in Cachexia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with cachexia as defined by Fearon criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Dose escalation cohorts of AV-380 administered by IV infusion
Biological: AV-380
AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Assessment of adverse events (AEs)
AEs as characterized by incidence, type, frequency, and severity (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\])
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose
Toxicity
Dose-limiting Toxicity (DLT) events observed at increasing doses of AV-380
Time frame: While receiving study drug (up to 4 months)
Laboratory Abnormalities
Laboratory abnormalities as characterized by type, frequency, severity (graded according to NCI-CTCAE v5.0) and timing.
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Cmax
Maximum observed plasma concentration for AV-380
Time frame: From first dose to the last follow-up visit approximately 60-days post dose.
Tmax
Time to reach the Cmax for AV-380
Time frame: From first dose to the last follow-up visit approximately 60-days post dose
AUC(0-t)
Area under the plasma concentration-time curve from zero time to the last measurable point for AV-380
Time frame: From first dose to the last follow-up visit approximately 60-days post dose.
Immunogenicity
Serum levels of Anti-Drug Antibody (ADA) against AV-380 and their potential relationship with AEs and serum levels of GDF-15
Time frame: From first dose to the last follow-up visit approximately 60-days post dose.
Weight
Change from baseline body weight during the study
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Patient-Reported Outcomes
Change from baseline in the following questionnaires: Functional Assessment of Anorexia Cachexia Therapy (FAACT); Patient global impression of severity (PGI-S) and patient global impression of change (PGI-C) for appetite, fatigue, and physical activity.
Time frame: From enrollment to the end of treatment, approximately 4 months
Lumbar (L3) Skeletal Muscle Index (L3SMI)
Measurement of a cross-sectional area of muscle at the level of the third lumbar vertebra (L3) using computed tomography (CT) scan
Time frame: From enrollment to the end of treatment, approximately 4 months
Physical Function
Change from baseline in physical function endpoints, including Short Physical Performance Battery test and digital measures of non-sedentary time
Time frame: From enrollment to the end of treatment, approximately 4 months
Serum level of GDF-15
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Albumin and CRP
Change from baseline in albumin and CRP levels
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Tumor status
Evaluate the effect of AV-380 on tumor burden and tumor status, per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1)
Time frame: From enrollment to the last follow-up visit approximately 60-days post dose.
Biomarkers
including activin A and cytokine levels (e.g., monocyte chemoattractant protein-1 \[MCP-1\] and proinflammatory)
Time frame: From first dose to the last follow-up visit approximately 60-days post dose.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Aug 2026, 37 months.
Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 37 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2026 → Aug 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilogrotug